![]() The analysis sample (n = 154) was 93.5% white and 63.0% female. Known-groups validity was evaluated based on BSA severity categories, and the ability to detect change was evaluated based on improvement in the subject's global assessment (SGA). Construct validity was evaluated by correlations between PSI scores and body surface area (BSA) affected by psoriasis and selected Short Form 36 (SF-36) health survey domains. Reliability was assessed using Cronbach's alpha (internal consistency) and intraclass correlation coefficients (ICCs) for PSI scores in patients with stable disease (test-retest). Unidimensionality and item evaluation were assessed using factor and Rasch analyses. This was a secondary analysis of pooled data from a phase II study evaluating the efficacy of brodalumab in patients with PsA. The PSI is an 8-item, patient-reported outcome measure of the severity of psoriasis signs and symptoms. ![]() To evaluate the measurement properties of the Psoriasis Symptom Inventory (PSI) in psoriatic arthritis (PsA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |